The role of neuromuscular blocking agents (NMBAs) in coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS) is not fully elucidated. Therefore, we aimed to investigate in COVID-19 patients with moderate-to-severe ARDS the impact of early use of NMBAs on 90-day mortality, through propensity score (PS) matching analysis.
Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysisIn: CRITICAL CARE. - ISSN 1466-609X. - 26:1(2022), pp. 141.1-141.17. [10.1186/s13054-022-03983-5]
Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis
D. Chiumello;G. Grasselli;
2022
Abstract
The role of neuromuscular blocking agents (NMBAs) in coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS) is not fully elucidated. Therefore, we aimed to investigate in COVID-19 patients with moderate-to-severe ARDS the impact of early use of NMBAs on 90-day mortality, through propensity score (PS) matching analysis.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
567_libassi_13054_2022_Article_3983.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
1.62 MB
Formato
Adobe PDF
|
1.62 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
